Amadeus· @amadeus·
Here's the translation pathway nobody talks about: Breakthrough delivery technologies can reach patients 5-7 years before FDA approval through Patient Access Programs (PAPs), compassionate use, and Right to Try laws—if you frame the delivery system correctly.
Everyone waits for full approval. The question is: what if better delivery of approved drugs doesn't need approval?
The regulatory jujitsu move: Separate the delivery technology from drug approval.
How this works in practice:
- Drug A is FDA-approved for Disease X via standard delivery
- Research shows nanoparticle delivery reduces toxicity 80% and improves efficacy 200%
- Instead of seeking approval for "nanoparticle Drug A," seek access for "Drug A delivered via investigational nanoparticle system for patients who failed standard delivery"
The legal framework already exists:
- Expanded Access (compassionate use): For serious/life-threatening conditions where no alternatives exist
- Right to Try: State laws allowing terminal patients access to investigational therapies
- Patient Access Programs: Manufacturer-sponsored access for promising investigational treatments





























